| 1. |
Debate over the WHO-ISH statement on calcium antagonists |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 2-2
&NA;,
Preview
|
PDF (1224KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 2. |
Angiotensin II antagonists offer additional benefits |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 3-4
Robert Carlson,
Preview
|
PDF (2231KB)
|
|
摘要:
Orally active angiotensin II antagonists that are specifically aimed at blocking the angiotensin II type 1 (AT1) receptor (such as valsartan, losartan potassium and irbesartan), were developed primarily for the treatment of hypertension. However, there is evidence that combining an AT1-receptor antagonist with an ACE inhibitor can confer important benefits in patients with hypertension and renal insufficiency. The good tolerability of combination therapy with valsartan plus an ACE inhibitor, the unexpected benefit of reduced serum uric acid levels with losartan potassium therapy, and an explanation of why blocking AT1receptors could reduce end-organ failure were discussed at the American Society of Nephrology annual meeting [San Antonio, US; November 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 3. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 4-4
&NA;,
Preview
|
PDF (1133KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 4. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 5-5
&NA;,
Preview
|
PDF (1146KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 5. |
Isotretinoin improves QOL for patients with acne |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 6-6
&NA;,
Preview
|
PDF (1182KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 6. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 7-7
&NA;,
Preview
|
PDF (1056KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 7. |
News from the 61st National Scientific Meeting of the American College of Rheumatology (ACR)Washington DC, US Nov 1997 |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 8-8
&NA;,
Preview
|
PDF (1150KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 8. |
Bromocriptine monotherapy: potential in Parkinson's disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 9-9
&NA;,
Preview
|
PDF (1030KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 9. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 10-10
&NA;,
Preview
|
PDF (1148KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 10. |
Abciximab enhances thrombolytic therapy in acute MI |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1115,
1997,
Page 11-12
Larry Prescott,
Preview
|
PDF (2310KB)
|
|
摘要:
Combination therapy involving the administration of a glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonist, such as abciximab, with thrombolytic therapy may be the treatment approach of the future for patients with acute myocardial infarction (MI). Interim results from the Thrombolysis in Myocardial Infarction (TIMI) 14 trial show that treatment in such patients with abciximab [‘ReoPro’; Centocor], plus low-dose thrombolytic agents facilitates thrombolysis. These results were presented at the 70th Scientific Sessions of the American Heart Association [Orlando, US; November 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
首页
